CN102491966B - Piperonyl pentylene acid sodium and application on blood lipid reduction thereof - Google Patents

Piperonyl pentylene acid sodium and application on blood lipid reduction thereof Download PDF

Info

Publication number
CN102491966B
CN102491966B CN201110395920.4A CN201110395920A CN102491966B CN 102491966 B CN102491966 B CN 102491966B CN 201110395920 A CN201110395920 A CN 201110395920A CN 102491966 B CN102491966 B CN 102491966B
Authority
CN
China
Prior art keywords
group
piperonyl
density lipoprotein
cholesterol
application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201110395920.4A
Other languages
Chinese (zh)
Other versions
CN102491966A (en
Inventor
博日吉汗格日勒图
娜日苏
昭日格图
王明芳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BORIJIHAN GERILEITU
Original Assignee
BORIJIHAN GERILEITU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BORIJIHAN GERILEITU filed Critical BORIJIHAN GERILEITU
Priority to CN201110395920.4A priority Critical patent/CN102491966B/en
Publication of CN102491966A publication Critical patent/CN102491966A/en
Priority to PCT/CN2012/085385 priority patent/WO2013078983A1/en
Application granted granted Critical
Publication of CN102491966B publication Critical patent/CN102491966B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses piperonyl pentylene acid sodium, pharmaceutical compositions or health care products containing the piperonyl pentylene acid sodium, a method for preparing the piperonyl pentylene acid sodium and application of the piperonyl pentylene acid sodium on blood lipid reduction. The application includes the application for preparing pharmaceuticals or the health care products which are used for reducing serum total cholesterol, low density lipoprotein cholesterol and triglyceride and preventing high density lipoprotein cholesterol from being reduced.

Description

The application of GB-Na and reducing blood-fat thereof
Technical field
The invention belongs to medical technical field, more particularly, relate to the application of GB-Na and reducing blood-fat thereof.
Background technology
Sickness rate, the mortality ratio of coronary heart disease rise rapidly nearly decades both at home and abroad, have reached 200,000,000 left and right crowds in China's hyperlipidemia associated patient; Annual 7000 ten thousand people in the whole world die from the relative disease that hyperlipidemia causes.Modern medicine study shows, (Coronary heart disease, CHD) is closely related for hyperlipemia and atherosclerosis (Atherosclerosis, AS) and coronary heart disease.The application of hypolipidemic is to cure hyperlipidemia, reduce deaths from heart disease rate the most effective medical procedures (Yang Shijie, Su Ruhao, etc. the application present situation of hypolipidemic and progress [J]. medical forum magazine, 2006,27 (1): 90-92).For improving prevention, the treatment ability of China to hyperlipidemia and cardiovascular and cerebrovascular disease, researching and developing new lipopenicillinase medicinal compound and new drug has become China medical sci-tech worker's important goal.
Conventional chemical lipid lowerers has following several both at home and abroad: 1. Statins; 2. the special class of shellfish; 3. nicotinic acid class; 4. cholic acid chelating (resene) agent; 5. polyenoid class etc.External hypolipidemic is studied main direction: 1. the novel cholesterol absorption inhibitor of research, represents that medicine is for wheat (Ezetimibe, Zetia) according to pool; 2. research cholesteryl ester acyltransferase (ACAT) inhibitor, this class medicine has been opened up the treatment of hypercholesterolemia mechanism.3. research novel form and compound drug combination.Wherein have: coupling of lovastatin controlled release tablet, slowly-releasing niacin preparation Nispan, fenofibrate micronize capsule, the special class of shellfish and Statins etc.Chemicals research aspect in continually developing and thering is novel mechanism hypolipidemic, various can alleviate adverse drug reaction, the novel form heightening the effect of a treatment and compound preparation also sequential use in clinical, obtained good therapeutic action.
Piper nigrum is medicinal and edible plant, is domestic and international conventional food seasoning, records in " Chinese Pharmacopoeia " (227 pages of versions in 2010) and " China's book on Chinese herbal medicine " (287 pages of anaesthetic volumes).Piper nigrum, English name: PIPERIS FRUCTUS, this product is dry near maturation or the mature fruit of piperaceae plant pepper Piper nigrum L..Autumn Mo gathers in the time that time the spring, fruit was sap green, dries, and be piper nigrum.Proterties: piper nigrum is spherical in shape, diameter 3.5～5mm.Surface chocolate, tool swells netted wrinkle, and there are tiny style vestiges on top, and base portion has the scar coming off from fruit axle.Matter is hard, and exocarp is peelable, endocarp canescence or faint yellow.Section yellow-white, mealiness, in have little space.Gas fragrance, taste is pungent.Nature and flavor with return through: pungent, heat.Return stomach, large intestine channel.Function with cure mainly: warming spleen and stomach for dispelling cold, lower gas, dissolving phlegm.For gastrofrigid vomiting, stomachache is had loose bowels, poor appetite, and epilepsy phlegm is many.
" Ge Genqin " is that the main component of the lipid-lowering health food that gone on the market (authentication code: exhale and defend No. 341st, food word 2002) is also the alkaloid extracting with in the plants such as the piperaceae plant Bi roots of grass, pepper, and its main component is piperine.
2002 start, Borijihan Geriletu, gold stake, Zhao Ruiguo, Bao Lanlan, Wu Yong, fiber crops spring outstanding person, Han Jingfen etc., piperaceae plant Bi roots of grass ethanol extraction and derivative thereof have been done to a large amount of research work, isolate first enough piperonyl acid amides crude substance: Bi roots of grass quinoline Pipernonaline, C 21h 27nO 3, PPA Piperlonguminine, C 16h 19nO 3with piperine Piperine, C 17h 19nO 3.
Years of researches have done in our research group, have found a kind of Fructus piperis nigrum extract piperonyl acid amides crude substance with reducing blood lipid; Referring to the Chinese invention patent of the submissions such as Borijihan Geriletu in 2004, Na Shengsang, gold stake, Zhao Ruiguo, patent No. ZL200410096611.7.
Summary of the invention
Contriver has been surprisingly found out that the sodium salt of piperonyl pentadienoic acid through a large amount of research, this compound has excellent reducing blood lipid.
The object of this invention is to provide GB-Na.
Second object of the present invention is to provide the medicinal compositions or the protective foods that comprise GB-Na.
The 3rd object of the present invention is to provide the preparation method of GB-Na.
The 4th object of the present invention is to provide the application of GB-Na reducing blood-fat.
In one embodiment of the present invention, the invention provides GB-Na.
In embodiments of the invention, GB-Na or piperinic acid sodium or GB-Na refer to the compound of lower array structure:
Figure BDA0000115588910000031
In one embodiment of the present invention, the invention provides the medicinal compositions or the protective foods that comprise GB-Na.Here, the route of administration of the medicinal compositions of described GB-Na comprises oral administration or parenteral administration.The medicinal compositions of GB-Na provided by the present invention or protective foods, except activeconstituents GB-Na, also comprise pharmaceutically or acceptable auxiliary material on protective foods further.For those of ordinary skills, GB-Na of the present invention is prepared into oral drug preparation, injection, protective foods can be prepared according to prior art, for example, " pharmaceutics " (the 6th edition) of Cui Defu chief editor, People's Health Publisher, in August, 2007, be prepared into liquid preparation (as oral liquid, injection liquid etc.), solid preparation (tablet, capsule etc.).For those of ordinary skills, the consumption of GB-Na of the present invention every day can be 10mg to 5g, can adopt once a day, or every day two to three times.
In one embodiment of the present invention, the invention provides the preparation method of GB-Na, comprise piperinic acid and NaOH neutralization reaction, thereby obtain GB-Na.Here, the piperinic acid of employing, it is originated referring to Jingfen Han, Gereltu Borjihan; Synthesis and anti-hyperlipidemic activity of a novel starch piperinic ester, Carbohydrate Polymers, 11, July 2007,7..
In a kind of preferred embodiment of the present invention, the invention provides the preparation method of GB-Na, wherein, piperinic acid is the piperonyl pentadiene acid esters of piperonyl pentadienoic acid (GB-H) or non-piperonyl pentadienoic acid, more preferably, be piperonyl pentadienoic acid (GB-H).
In a kind of preferred embodiment of the present invention, the invention provides the preparation method of GB-Na, wherein, piperinic acid and NaOH are dissolved in and in C1-C4 alkanol, carry out neutralization reaction; Here, described C1-C4 alkanol is preferably ethanol.
In a kind of preferred embodiment of the present invention, the invention provides the preparation method of GB-Na, piperonyl pentadiene Cyclohexamide (piperine, GB-O) be dissolved in ethanol, add KOH, reflux 6-16 hour, cooling leaving standstill, suction filtration, both the crystal of GB-K (GB-K, GB-K).GB-K is soluble in water, and with sulfuric acid acidation, the precipitation of generation is piperonyl pentadienoic acid (piperinic acid, GB-H), suction filtration.Piperonyl pentadienoic acid is dissolved in hot ethanol, in hot solution, add sodium hydroxide ethanolic soln, the precipitation producing is GB-Na (piperinic acid sodium, GB-Na), be chilled to room temperature suction filtration, with three throw out GB-Na of absolute ethanol washing, suction filtration, dry, obtain faint yellow solid GB-Na (synthesis process flow diagram is referring to Fig. 7).
In one embodiment of the present invention, the invention provides the preparation method of GB-Na, comprise piperine and NaOH hydrolysis reaction, thereby obtain GB-Na.Here, the piperine of employing, it is originated referring to CN 1330545A.
In a kind of preferred embodiment of the present invention, the invention provides the preparation method of GB-Na, wherein, piperine is the piperonyl Pentadienamide of piperonyl pentadiene Cyclohexamide (GB-O) or non-piperonyl pentadiene Cyclohexamide (GB-O), more preferably, be piperonyl pentadiene Cyclohexamide (GB-O).
In a kind of preferred embodiment of the present invention, the invention provides the preparation method of GB-Na, wherein, piperine and NaOH are dissolved in being hydrolyzed in C1-C4 alkanol and react; Here, described C1-C4 alkanol is preferably ethanol.
In a kind of preferred embodiment of the present invention, the invention provides the preparation method of GB-Na, comprise piperine and NaOH are dissolved in to ethanol, reflux 16-26 hour, leave standstill coolingly, produce the crystallization of hydrolyzate, crystallize to neutrality by washing with alcohol, be dried, can obtain faint yellow solid (being GB-Na, GB-Na).This reaction is as follows:
Figure BDA0000115588910000041
In one embodiment of the present invention, the invention provides a kind of GB-Na in the application of preparing in blood lipid-lowering medicine.
In one embodiment of the present invention, the invention provides the application of a kind of GB-Na in the medicine of preparation reduction serum total cholesterol.
In one embodiment of the present invention, the invention provides the application of a kind of GB-Na in the medicine of preparation reduction low density lipoprotein cholesterol.
In one embodiment of the present invention, the invention provides the application of a kind of GB-Na in the medicine of preparation prevention high density lipoprotein cholesterol reduction.
In one embodiment of the present invention, the invention provides the application of a kind of GB-Na in the medicine of preparation reduction triglyceride level.
In one embodiment of the present invention, the invention provides a kind of GB-Na in the application of preparing in blood fat reducing health products.
In one embodiment of the present invention, the invention provides the application of a kind of GB-Na in the healthcare products of preparation reduction serum total cholesterol.
In one embodiment of the present invention, the invention provides the application of a kind of GB-Na in the healthcare products of preparation reduction low density lipoprotein cholesterol.
In one embodiment of the present invention, the invention provides the application of a kind of GB-Na in the healthcare products of preparation prevention high density lipoprotein cholesterol reduction.
In one embodiment of the present invention, the invention provides the application of a kind of GB-Na in the healthcare products of preparation reduction triglyceride level.
The present invention is surprisingly found out that unforeseeable effect by test: GB-Na is better than contrasting medicine Simvastatin in significance aspect reduction serum total cholesterol, triglyceride level and low density lipoprotein cholesterol, and, be also better than piperonyl pentadienoic acid; And there is the effect of prevention reduction high density lipoprotein cholesterol.
Brief description of the drawings
That Fig. 1 represents is the 500MHz of GB-Na 1h-NMR spectrogram.
What Fig. 2 represented is GB-Na (GB-Na) 125MHz 13C-NMR nuclear magnetic resonance map.
What Fig. 3 represented is piperonyl pentadiene Cyclohexamide (GB-O), piperonyl pentadienoic acid (GB-H), GB-K, the GB-Na measurement result to the effect of rat serum total cholesterol level.
What Fig. 4 represented is GB-O, GB-H, GB-K, the GB-Na measurement result to the effect of rat serum content of triglyceride.
What Fig. 5 represented is GB-O, GB-H, GB-K, the GB-Na measurement result to the effect of rat serum low density lipoprotein cholesterol content.
What Fig. 6 represented is GB-O, GB-H, GB-K, the GB-Na measurement result to the effect of rat serum high density lipoprotein cholesterol content.
What Fig. 7 represented is the synthesis process flow diagram of GB-Na.
Embodiment
Embodiment 1
The preparation method one of GB-Na (GB-Na)
Piperonyl pentadiene Cyclohexamide (piperine, GBO) is dissolved in ethanol, adds KOH, reflux 6-16 hour, cooling leaving standstill, suction filtration, both the crystal of GB-K (GB-K, GB-K).GB-K is soluble in water, and with sulfuric acid acidation, the precipitation of generation is piperonyl pentadienoic acid (piperinic acid, GB-H), suction filtration.Piperonyl pentadienoic acid is dissolved in hot ethanol, in hot solution, add sodium hydroxide ethanolic soln, the precipitation producing is GB-Na (piperinic acid sodium, GB-Na), be chilled to room temperature suction filtration, with three throw out GB-Na of absolute ethanol washing, suction filtration, dry, obtain faint yellow solid GB-Na.The molecular formula C of GB-Na 12h 9naO 4, ESI-MS m/z:217.0[M-Na] -.Concrete reaction conditions is as follows:
Figure BDA0000115588910000061
Embodiment 2
The preparation method two of GB-Na (GB-Na)
Piperine (being piperonyl pentadiene Cyclohexamide (GB-O)) and a certain amount of NaOH are dissolved in to ethanol, reflux 16-26 hour, leave standstill cooling, produce the crystallization of hydrolyzate, crystallize to neutrality by washing with alcohol, vacuum-drying, can obtain faint yellow solid (GB-Na, GB-Na).The molecular formula C of GB-Na 12h 9naO 4, ESI-MS m/z:217.0[M-Na] -.Concrete reaction conditions is as follows:
Embodiment 3
The structure of GB-Na (GB-Na) is determined
500MHz Brooker nuclear magnetic resonance analyser, the deuterated water of solvent, the 500MHz of mensuration GB-Na 1h-NMR spectrogram (seeing Fig. 1); GB-Na (GB-Na) 125MHz 13c-NMR nuclear magnetic resonance map (seeing Fig. 2).
GB-Na 1h-NMR spectrogram chemical shift data table, the ppm of unit
Figure BDA0000115588910000073
Figure BDA0000115588910000081
GB-Na 13c-NMR spectrogram chemical shift data table, the ppm of unit
Figure BDA0000115588910000082
Embodiment 4
GB-Na (GB-Na) rat reducing blood-fat drug effect simultaneous test
(1) experiment material
Experiment reagent: piperonyl pentadiene Cyclohexamide (GB-O), piperonyl pentadienoic acid (GB-H), GB-K (GB-K), the preparation of GB-Na (GB-Na, embodiment 1) University of the Inner Mongol;
Simvastatin (SVTT) is produced by Haizheng Medicine Stock Co., Ltd., Zhejiang Prov; Product batch number: B1091138
Total cholesterol test kit, is produced by Zhongsheng Beikong Biological Science & Technology Co., Ltd.; Lot identification mark: 201009, production licence number: capital medicine prison tool is produced and permitted 20000271
Triglyceride Reagent box, is produced by Zhongsheng Beikong Biological Science & Technology Co., Ltd.; Product batch number: 201009, production licence number: capital medicine prison tool is produced and permitted 20000271
High density lipoprotein cholesterol test kit, is produced by Zhongsheng Beikong Biological Science & Technology Co., Ltd.; Product batch number: 201007, production licence number: capital medicine prison tool is produced and permitted 20000271
Low density lipoprotein cholesterol test kit, is produced by Zhongsheng Beikong Biological Science & Technology Co., Ltd.; Product batch number: 201007, production licence number: capital medicine prison tool is produced and permitted 20000271
Cholesterol is produced by Beijing bispin microbiological culture media products factory; Product batch number: 20100619
Sodium cholic acid is produced by Haidian District, Beijing City microbiological culture media products factory; Product batch number: 0100525
Laboratory apparatus: PRONTO EVOLUTION full automatic biochemical apparatus (Italy produces); TDL-5 whizzer (Anting Scientific Instrument Factory, Shanghai);
Laboratory animal: Wistar male white rat, purchase from Beijing Vital River Experimental Animals Technology Co., Ltd..
High lipid food formula: cholesterol 3%, lard 10%, Sodium cholic acid 0.5%, basal feed 86.5% (formula: flour 17.14%, ground rice 8.57%, corn 17.14%, wheat bran 21%, fish meal 1.71%, salt 0.857%, VITAMIN 0.085%, beans material 17.14%)
(2) experimental technique
Get 60 of Wistar big white mouse, body weight 150 ± 10g, male, feed after 5 days with common standard feed, be divided at random 6 groups, 10 every group.I group is blank group (blank group at the common standard feed of feeding), and II group is high lipid food model control group, and III group is Simvastatin 10mg/kg group, and IV group is GB-O group, and V group is GB-H group, and VI group is GB-K group, and VII group is GB-Na group.High lipid food model control group is filled with and is fed distilled water in the high lipid food of feeding, III, IV, V, VI, VII group are filled with respectively and are fed required Simvastatin, GB-O, GB-H, GB-K, GB-Na suspension (grind and prepare with 0.5% Xylo-Mucine CMC-Na) in the high lipid food of feeding, dosage is 0.046mmol/kg, and the high lipid food amount of feeding is every 20g/ days.(grouping situation and respectively organize dosage in table 1)
Table 1 grouping situation and respectively organize dosage
Figure BDA0000115588910000091
(3) Observe and measure and mathematical statistics method
Measure and record big white mouse body weight every day, each group is filled with and is fed administration 14 days, 22 DEG C of room temperatures, relative humidity 40-50% by body weight.Freely drink water after 16 hours fasting in the 14th day, get blood from aorta, place blood coagulation 30min, the centrifugal 15min separation of serum of 3000r/min, adopt enzymic colorimetric on full automatic biochemical apparatus, to measure serum total cholesterol (TC) value, triglyceride level (TG) value, phospho-wolframic acid-magnesium precipitate method measures high density lipoprotein cholesterol (HDL) value and polyvinyel sulfate is measured low density lipoprotein cholesterol (LDL) value.
The data obtained is carried out to statistical procedures, and with mean ± standard deviation, (x ± s) represent, the significance of difference is judged with T inspection.The computation of P value is: hyperlipidemia model group and blank group relatively obtain, and other are relatively obtained by reagent group and hyperlipidemia model group.(p < 0.01 is utmost point significant difference, p < 0.05 is significant difference, 0.05 < p < 1 is for there being effect trend there was no significant difference, and p > 1 is retroaction)
(4) test philosophy
Enzymic colorimetric (CHOD-PAP) is measured total cholesterol (Total Cholesterol, TC)
Temperature of reaction is 37 DEG C, first use CEH (CEH) that the cholesterol ester in serum (CE) is hydrolyzed to free cholesterol (FC) and lipid acid, use again rCO (COD) that all FC in serum are oxidized to ch-4-alkene-3-ketone, and produce H 2o 2, the latter reacts (Trinder reaction) with 4-AA (4-AAP) and 4-chlorophenol and generates red quinonimine, colorimetric estimation under 500nm wavelength under peroxidase (POD) effect.
Enzyme is measured triglyceride level (Triglycerides, TG) than method (GPO-PAP)
Temperature of reaction is 37 DEG C, first using lipoprotein lipase (LPL) is glycerine and lipid acid by the triglyceride hydrolysis in serum, under the effect of glycerol kinase (GK), glycerine and ATP reaction generate glycerol-3-phosphate and ADP, under the effect of GPO (GPO), glycerol-3-phosphate is oxidized by oxygen into phosphodihydroxyacetone and H 2o 2, under peroxidase (POD) effect, H 2o 2react (Trinder reaction) with 4-AA (4-AAP) and 4-chlorophenol and generate red quinonimine, colorimetric estimation under 500nm wavelength.
Polyvinyl sulfuric acid salt (PVS) Precipitation Determination low density lipoprotein cholesterol (Low Density Lipoprotein Cholesterol, LDL-C)
LDL in serum can be precipitated by PVS, on the basis with aforesaid enzymatic assays serum TC and this supernatant C h, deducts the latter from the former, is LDL-C, for promoting LDL precipitation to add in right amount the only methyl ether of polyoxyethylene glycol (PEGME).
Phospho-wolframic acid-magnesium precipitate method is measured high density lipoprotein cholesterol (High Density Lipoprotein Cholesterol, HDL-C)
Low-density lipoprotein (LDL) in serum and vldl (VLDL) supernatant liquor after phospho-wolframic acid-magnesium precipitate are high-density lipoprotein (HDL) (HDL), its cholesterol level enzymatic assays.
(5) experimentation on animals test data
GB-O, GB-H, GB-K, GB-Na list respectively table 2-5 in to the data of hyperlipidemia model big white mouse blood fat evaluation test.Serum total cholesterol pH-value determination pH the results are shown in Table 2, and triglyceride level pH-value determination pH the results are shown in Table 3, and low density lipoprotein cholesterol pH-value determination pH the results are shown in Table 4, and high density lipoprotein cholesterol pH-value determination pH the results are shown in Table 5.
The 15th day big white mouse serum total cholesterol (TC) content (mmol/L of unit) after table 2, administration
The 15th day big white mouse serum triglyceride (TG) content (mmol/L of unit) after table 3. administration
Figure BDA0000115588910000112
Figure BDA0000115588910000121
The 15th day big white mouse serum low-density LP cholesterol (LDL) content (unit: mmol/L) after table 4. administration
The 15th day big white mouse serum High Density Lipoprotein Cholesterol (HDL) content (mmol/L of unit) after table 5. administration
Figure BDA0000115588910000123
Figure BDA0000115588910000131
(6) lipid-lowering test result and comparative analysis
GB-O, GB-H, GB-K, GB-Na list respectively table 6-9 in to the evaluation result of hyperlipidemia model big white mouse blood fat.To rat serum total cholesterol level measurement result analysis in table 6 and Fig. 3, rat serum content of triglyceride measurement result is divided in table 7 and Fig. 4, to the interpretation of result of rat serum low density lipoprotein cholesterol assay in table 8 and Fig. 5, to the interpretation of result of rat serum high density lipoprotein cholesterol assay in table 9 and Fig. 6.
Effect to rat serum total cholesterol TC:
Each group relatively II group (hyperlipidemia model control group) has the effect of the total cholesterol of reduction.III group (Simvastatin 10mg/kg), IV group (GB-O), V group (GB-H), VI group (GB-K), VII group (GB-Na) have utmost point significant difference.
The interpretation of result of table 6 rat serum total cholesterol (TC) assay
Figure BDA0000115588910000132
Note: P value refers to that each group is compared with II group: P < 0.05, there were significant differences; P < 0.01, has utmost point significant difference.
Effect to rat serum triglyceride level TG:
Rat serum TG shows (in table 7 and Fig. 4), and by making comparisons with II group (hyperlipidemia model control group), each group has the effect of the triglyceride level of reduction.There were significant differences for V group (GB-H).III group (Simvastatin 10mg/kg) has utmost point significant difference, IV group (GB-O) to have utmost point significant difference, VI group (GB-K) to have utmost point significant difference, VII group (GB-Na) to have utmost point significant difference.
Table 7 rat serum triglyceride level (TG) assay interpretation of result (mmol/L of unit)
Figure BDA0000115588910000141
Note: P value refers to that each group is compared with II group: P < 0.05, there were significant differences; P < 0.01, has utmost point significant difference.
Effect to rat serum low density lipoprotein cholesterol LDL-C:
Rat serum LDL-C result shows (in table 8 and Fig. 5), by making comparisons with II group (hyperlipidemia model control group), III group (Simvastatin 10mg/kg), IV group (GB-O), V group (GB-H), VII group (GB-Na) all have the effect that reduces serum low-density LP cholesterol value.There were significant differences for VI group (GB-K).
Table 8 rat serum low density lipoprotein cholesterol (LDL-C) assay interpretation of result (mmol/L of unit)
Figure BDA0000115588910000142
Figure BDA0000115588910000151
Note: P value refers to that each group is compared with II group: P < 0.05, there were significant differences; P < 0.01, has utmost point significant difference.
Effect to rat serum high density lipoprotein cholesterol HDL-C:
HDL-C result shows (in table 9 and Fig. 6), by making comparisons with III group (Simvastatin 10mg/kg), IV group (GB-O), V group (GB-H), VI group (GB-K), VII group (GB-Na) has the effect of high density lipoprotein increasing cholesterol.
Table 9 rat serum high density lipoprotein cholesterol (HDL-C) assay interpretation of result (mmol/L of unit)
Figure BDA0000115588910000152
Note: P value refers to that each group is compared with II group: P < 0.05, there were significant differences; P < 0.01, has utmost point significant difference.
(7) test-results and conclusion
Aspect reduction total cholesterol, experimental result shows all there is utmost point significant difference between GB-Na, GB-K, GB-O, GB-H and hyperlipidemia model control group.Illustrate that GB-Na can prevent increasing of total cholesterol, and, GB-Na prevention total cholesterol to increase aspect more remarkable.
Aspect reduction triglyceride level, GB-Na group has utmost point significant difference with hyperlipidemia model control group.GB-Na can prevent triglyceride level increase effect fairly obvious.
Aspect low-density lipoprotein, GB-Na group has reducing effect with hyperlipidemia model control group.This shows that GB-Na can prevent low-density lipoprotein to increase.
Aspect high density lipoprotein cholesterol, GB-Na group has rising effect with control group.This shows that GB-Na can prevent to reduce high density lipoprotein cholesterol.
In a word, GB-Na has regulating blood lipid action.

Claims (2)

1. GB-Na is in the application of preparing in serum regulating drug, and here, described adjusting blood fat refers to and reduces serum total cholesterol, reduces low density lipoprotein cholesterol, prevents high density lipoprotein cholesterol to reduce and reduce triglyceride level.
2. GB-Na regulates the application in blood fat healthcare products in preparation, and here, described adjusting blood fat refers to and reduces serum total cholesterol, reduces low density lipoprotein cholesterol, prevents high density lipoprotein cholesterol to reduce and reduce triglyceride level.
CN201110395920.4A 2011-12-02 2011-12-02 Piperonyl pentylene acid sodium and application on blood lipid reduction thereof Active CN102491966B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201110395920.4A CN102491966B (en) 2011-12-02 2011-12-02 Piperonyl pentylene acid sodium and application on blood lipid reduction thereof
PCT/CN2012/085385 WO2013078983A1 (en) 2011-12-02 2012-11-28 Sodium Piperonyl Pentadienoate and Use of the Same for Lowering Blood Lipid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201110395920.4A CN102491966B (en) 2011-12-02 2011-12-02 Piperonyl pentylene acid sodium and application on blood lipid reduction thereof

Publications (2)

Publication Number Publication Date
CN102491966A CN102491966A (en) 2012-06-13
CN102491966B true CN102491966B (en) 2014-07-02

Family

ID=46183836

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201110395920.4A Active CN102491966B (en) 2011-12-02 2011-12-02 Piperonyl pentylene acid sodium and application on blood lipid reduction thereof

Country Status (2)

Country Link
CN (1) CN102491966B (en)
WO (1) WO2013078983A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104758280A (en) * 2011-08-12 2015-07-08 博日吉汗格日勒图 Application of potassium piperonyl pentadienoate in blood fat reduction
CN102491966B (en) * 2011-12-02 2014-07-02 博日吉汗格日勒图 Piperonyl pentylene acid sodium and application on blood lipid reduction thereof
CN103919135B (en) * 2014-04-25 2016-06-01 哈尔滨贝加尔泰生物工程有限公司 White birch bacterium health care oral liquid and making method
CN105348250A (en) * 2015-10-20 2016-02-24 吐尔孙拜克·叶尔达 Medicinal compound pepper acid hexamethylene diamine and preparation process thereof
CN106432173B (en) * 2016-09-26 2018-09-25 内蒙古大学 A kind of breast cancer targeted drug potassium pepper of new chemical synthesis
CN109394761A (en) * 2018-12-18 2019-03-01 青岛大学 A kind of novel effect for reducing blood fat of piperine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1634029A (en) * 2004-12-03 2005-07-06 内蒙古大学 Use of pepper amide compound in preparation of drug or healthcare product for reducing blood fat

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06336417A (en) * 1993-03-31 1994-12-06 Shiseido Co Ltd Ultraviolet light absorber and external preparation for skin mixed with the same
CN1634030A (en) * 2004-12-03 2005-07-06 内蒙古大学 Use of piperic acid ester compound in preparation of drug or healthcare product for reducing blood fat
CN102491966B (en) * 2011-12-02 2014-07-02 博日吉汗格日勒图 Piperonyl pentylene acid sodium and application on blood lipid reduction thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1634029A (en) * 2004-12-03 2005-07-06 内蒙古大学 Use of pepper amide compound in preparation of drug or healthcare product for reducing blood fat

Also Published As

Publication number Publication date
WO2013078983A1 (en) 2013-06-06
CN102491966A (en) 2012-06-13

Similar Documents

Publication Publication Date Title
CN102491966B (en) Piperonyl pentylene acid sodium and application on blood lipid reduction thereof
CN105849111A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
CN105379886A (en) Black tea composition capable of preventing and treating hyperuricemia and preparation method thereof
CN102920696A (en) Application of mangiferin compound or mango extraction as pancreatic lipase inhibitor and to preparation of medicament or food for preventing and treating obesity
CN102283830A (en) Hypolipemic application of potassium piperonyl pentadienoate
CN101836975B (en) Application of isopentene group flavonoid compound used as pancreatic lipase inhibitor
Stefanucci et al. A comparative study on phytochemical fingerprint of two diverse Phaseolus vulgaris var. Tondino del Tavo and Cannellino bio extracts
Saikia et al. Bioactive Compounds and Health-Promoting Properties of Elephant Apple (Dillenia indica L.): A Comprehensive Review
CN102068557B (en) Application of Pu&#39;er tea extract in preparation of medicines for reducing blood fat
CN102177996B (en) Semen cannabis laxative tea and preparation method thereof
CN105796616B (en) Application of the Sha Peng in the drug or health care product of preparation treatment reducing blood lipid
CN102940650A (en) Propolis ethanol extract for dispeling the effects of alcohol, preparation method of propolis ethanol extract and application of propolis ethanol extract for producing enteric-coated tablets
CN105348250A (en) Medicinal compound pepper acid hexamethylene diamine and preparation process thereof
CN102302114A (en) Pollen-containing health-care food and preparation method thereof
CN105456277B (en) Application of the ganodenic acid acid activity position in preparing blood fat reducing health products and drug
CN103936710B (en) Piperonyl Pentadienamide derivatives that N-replaces and its preparation method and application
CN103054906A (en) Propolis ethanol extract for alleviating hangover and preparation method thereof, and application of propolis ethanol extract in producing buccal tablets
CN102406109A (en) Gynura bicolor jelly
CN110101689A (en) N-octacosanol is preparing the application in preventing liver injury drug
Youssef et al. Harnessing the Bioactive Potential of Limonium spathulatum (Desf.) Kuntze: Insights into Enzyme Inhibition and Phytochemical Profile
CN108503653B (en) A kind of naphthoquinone compound and its preparation with preparing the application in hypoglycemic product
CN109393486A (en) Blood fat reducing health products and preparation method thereof containing dendrobium candidum polysaccharide extractive
CN1973875A (en) Process of extracting Tatine compounds from Puer tea and the product
Tedi Study Literature: Acacia Plants Lower Blood Sugar
CN113694105B (en) Composition with blood fat reducing function and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant